CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries

Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries
  • Posted by: BIOCON

Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore

Biocon Q3FY21 Results
  • Posted by: BIOCON

Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director

Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
  • Posted by: BIOCON

Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ

Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
  • Posted by: BIOCON

Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US

Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
  • Posted by: BIOCON

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
  • Posted by: BIOCON

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

  • Posted by: BIOCON

Biocon Ranked Among Top 5 Biotech Employers Globally

  • Posted by: BIOCON

Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.

  • Posted by: BIOCON

Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>